TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.
Thiogenesis Therapeutics Corp has announced an increase in its non-brokered private placement offering from 2 million to 5.3 million common shares due to strong investor demand, raising approximately $4 million. The proceeds will be used to support clinical trial expenses for their lead product TTI-0102, which targets mitochondrial disorders, and for general working capital. This move is expected to bolster the company’s financial position and support its ongoing clinical trials, enhancing its potential impact in the biopharmaceutical industry.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, CA. The company is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S. It focuses on developing sulfur-containing prodrugs that serve as precursors to thiol-active compounds, with potential applications in treating serious pediatric diseases with unmet medical needs. Their lead product candidate, TTI-0102, is involved in active clinical trials for conditions such as MELAS, Leigh syndrome spectrum, Rett syndrome, and pediatric Metabolic Dysfunction-Associated Steatohepatitis.
Average Trading Volume: 39,876
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$36.58M
See more data about TTI stock on TipRanks’ Stock Analysis page.